glp-1 producers Drugs and the Physiology of Metabolic Health Looming GLP-1 drug patent expirations

About BioMedWire BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors

Storage and Administration Requirements GLP-1 medications require specific handling to maintain effectiveness and safety

A note on supplements The products included on this list are dietary supplements

This further underlines that the potent weight-reducing benefits of the bimodal compound are not linked to an aggravated adverse profile when compared to marketed incretin-based drugs such as semaglutide

Whats Coming: The BALANCE Model (May 2026) The biggest development in Medicaid GLP-1 coverage is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), announced by CMS in December 2025

Antihyperglycemic and blood pressure effects of empagliflozin in Black patients with type 2 diabetes mellitus and hypertension